Critical delays in aligning Africa’s pharmaceutical regulations with World Health Organisation (WHO) standards are jeopardising the continent’s R1.25-trillion ($70bn) goal. They aim to become a self-sufficient pharmaceuticals manufacturing hub, according to a top industry executive. Stavros Nicolaou, a senior executive at Aspen Pharmacare and chair of Pharmaceuticals Made in South Africa (Pharmisa), warned that this regulatory bottleneck is preventing African…